Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great bit of news!. Thanks.
Thank you, very much!
08/15/2024 50,252,550 shares now shorted as of August 15th.
Also, not a bad time for a Roth IRA Conversion!!!
Wow, thanks!
7,685,001 shorts covered & 13,887,333 shares added between June 1-14 and price dropped from .4513 to .4320
Interesting!
https://braintumourresearch.org/en-us/blogs/research-campaigning-news/whats-the-plan
Brain Tumour Research has contributed to a new paper which highlights the barriers and opportunities for the brain tumour research sector in the UK to accelerate progress for adult patients across the world.
Dr Karen Noble, our Director of Research, Policy and Innovation, is a named author of the position paper, which reviews the current landscape and identifies three cross-cutting themes and seven research priorities in order to improve outcomes for brain tumour patients.
Dr Noble said: “Despite the funding announcements in 2018, there remain a number of challenges and bottlenecks, spanning basic research to patient experience, that are slowing down our progress to find a cure for all types of brain tumours. The UK continues to have relatively fewer clinical trials compared to other countries and patient survival has not significantly improved in decades.”
Members of the UK National Cancer Research Institute (NCRI) Brain Group investigated the current brain tumour research landscape using information from expert panel sessions, reports published by Cancer Research UK (CRUK), the National Institute for Health and Care Research (NIHR) and the All-Party Parliamentary Group on Brain Tumours (APPGBT).
The resulting paper identified three cross-cutting themes including collaborative networks and initiatives, funding and training; and seven research priorities, encompassing prompter diagnosis, development of accessible, innovative and evidence-based clinical trials, treating every patient as a research patient, and the facilitation of living beyond a brain tumour.
“The recommendations made in this position paper are designed to inspire UK reform and provide focal points for future funding calls and partnerships, to accelerate progress towards better and longer life for adult brain tumour patients across the world.”
At Westminster this week a question from Alistair Strathern (Labour Mid Bedfordshire ) was answered. He asked the Secretary of State for Health and Social Care, "whether NHS England plans to provide dendric cell therapy for glioma".
Health Minister Stephenson Conservative answered that: "The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines, including medicines for glioma, to determine whether they represent a clinically and cost-effective use of resources. The NICE aims to publish guidance on new medicines as close as possible to licensing. Any medicine for glioma, recommended in draft NICE guidance, will be eligible for funding through the Cancer Drugs Fund from the point a positive draft guidance is published, in line with the standard arrangements for cancer medicines.
"On 24 April 2024, the NICE published draft guidance recommending a new treatment for glioma in children and young people that will be available to eligible patients once supply of the treatment is available (we reported on this in last week's update).
"There are currently no licensed dendritic cell therapies for glioma. A number of dendritic cell therapies are in development for the treatment of glioma, and any new licensed and NICE recommended treatments would be funded by NHS England, in line with NICE’s recommendations."
A new report published by the Teenage Cancer Trust warns that too many young people aged 13–24 are missing out on the chance to take part in clinical trials, leaving them unable to access innovative new treatments that could increase their chances of survival.
The report, which was developed after a year of consultation with young people the charity supports plus clinicians, academics, charities, and other experts, identifies the main barriers to participation and makes recommendations on how policymakers, the NHS, pharmaceutical industry, and researchers can help overcome these.
In the report, key stakeholders identified a lack of available trials as the key barrier. A lack of open trials impacts patients of all ages, but young people are uniquely disadvantaged because they are more likely to experience rare cancers or find themselves too old to take part in paediatric trials and too young for adult trials.
Other barriers identified include a lack of reliable easily searchable information about current trials for clinicians, and a lack of age-appropriate information for young people to aid their decision making. The report also highlights the need for trial participants to often travel long distances to take part, and the associated expense.
The Teenage Cancer Trust says the unique needs of young people are consistently overlooked in national efforts to increase access to trials – for example last year’s O’Shaughnessy Review on commercial clinical trials – and is calling for their views and experiences to be addressed as recommendations are developed and put into action.
To effectively measure reductions in inequality, the Teenage Cancer Trust is calling for data around the numbers of young people who are offered and participate in trials – and those for whom no trial is available – be consistently collected and transparently available.
Thomas said: “Access to clinical trials is a huge issue for the brain tumour community and we welcome this report from the Teenage Cancer Trust which highlights the barriers facing young people.
“Currently, only 5% of brain tumour patients enter the limited number of trials available, so any route to improvement must be listened to. In our new manifesto, we are calling on the Government to commit to increased participation of adult and paediatric brain tumour patients in clinical trials because equity of access is crucial if we are to find better treatments and, ultimately, a cure.”
This week Thomas attended Cancer52’s Members’ Meeting, which had a special Q&A with Professor Peter Johnson, National Clinical Director for Cancer. Cancer52 represents nearly 100 cancer charities, including Brain Tumour Research, united by their vision of seeing a better future for everyone affected by the rare and less common cancers, which account for more than half of all cancer deaths in the UK.
Professor Johnson said it was his aim to ensure that the NHS is as innovative possible. He spoke about the importance of lowering the barriers to the investigative process of cancers but noted that rare and less common cancers are still a challenge for the system. There are particular problems with brain cancer where the early diagnosis rates are quite low.
In terms of access to treatments, Professor Johnson said that the “NHS does reasonably well to gain access to drugs that have a good evidence base”. He said that the NHS was aware it needed to ensure value for taxpayers' money is maximised and that treatments are deemed effective.
With the news of trial opportunities being missed, barriers for our research sector and the need to get the dendritic cell therapies currently in development actually licensed, then it is clear our manifesto could not be more timely or more needed and that we must, and we will, push on on with our plans to have the commitments realised. Your role as brain tumour campaigner in this is critical now and in the build up to the General Election.
That is it for this week.
Although there has been the policy emphasis this week I am still going horseracing this week - this time at Newmarket. Please keep an eye on our social media to see the fantastic fundraising opportunities presented to us by our partnerships with The Jockey Club and The British Hat Guild - you may decide it is time to invest in that new hat!
Wishing you all a peaceful time until next Friday when we will be back with another campaigning update.
Hugh and Thomas
Thanks a lot!
So there has been 30M new shares bought this year from the company and the price has gone down to 51 cents from 70 cents. Would love to know the makeup of the buyers.
Interesting! What are the successful tactics that a small company has been able to use when there was an abundance of illegal shorts plus legal shorts betting against their company?
Thanks, Captain!
Apparently this has been a controlled release of shares to buyers for a very, very long time.
The question is, why?
Totally agree!
Excellent post.
Thanks!
Assessment
When approved they will submit to Canada
Thanks for the info.
Even though it is an ECN, can't it still be a signal?
Every morning at 8:00 OTCN puts in a bid and ask.
Is it a signal to the other market makers as to how they will trade that day?
It seems so.
Thank you. Very Good.
In court documents, when it states “Jury Demand: Plaintiff,” it signifies that the plaintiff (the party bringing the lawsuit) has formally requested a jury trial. Let’s break down what this means:
Jury Demand:
The term “jury demand” refers to the right of parties to request a trial by jury.
It ensures that parties have the option to have their case heard by a jury of their peers rather than solely by a judge.
Plaintiff’s Role:
The plaintiff is the individual or entity initiating the legal action.
By including “Jury Demand: Plaintiff” in court documents, the plaintiff is asserting their right to a jury trial.
Procedure:
The plaintiff typically includes this demand in their initial pleading (such as the complaint).
If the plaintiff does not explicitly make this demand, they may waive their right to a jury trial.
Other parties (such as the defendant) can also make a jury demand within a specified time frame.
Effect:
If the plaintiff’s demand is properly served and filed, the case will proceed to a jury trial.
The jury will then decide factual issues and render a verdict.
Remember that this notation ensures that parties have the opportunity to choose a jury trial when appropriate for their case
- from ChatGPT
Thanks for taking to the time to express your view and mine.
So True!
https://www.usinflationcalculator.com/inflation/historical-inflation-rates/
It all adds up over the years.
Gotta keep it under 2% every month.
It would be fun. If you ever have seen the movie "Dumb Money" you can understand the dilemma for investors during a short squeeze. The movie does a good job of showing this.
Remarks by Dr. Califf to the 2024 Biannual Conference of the NYU Grossman School of Medicine Working Group on Compassionate Use and Preapproval Access
JANUARY 30, 2024
https://www.fda.gov/news-events/speeches-fda-officials/remarks-dr-califf-2024-biannual-conference-nyu-grossman-school-medicine-working-group-compassionate
An interesting speech.
Nice, a very informative post for newbies!
There's a lot of good and different calculators on this website: (select at the top)
https://www.usinflationcalculator.com/inflation/historical-inflation-rates/
If anyone has been thinking of adding more shares, an opportunity like this does not always come along. It's a battle for shares right now for different reasons and all sorts of manipulators are working together and against each other at the same time, trying to gather something, but it's tough. One will kick themself eventually for not taking the chance now, if they seriously are buyers and don't pull the trigger. I believe a tactic may be to keep it between .51 and .58 for awhile. IMO
Let's hope not.
ilovetech, there is a big push right now.
As for CBDC's:
"“I will never allow the creation of a Central Bank Digital Currency”
– Donald Trump
At a New Hampshire campaign rally earlier this week he said CBDCs are dangerous, and he would never allow it if elected.
“This would be a dangerous threat to freedom, and I will stop it from coming to America. Such a currency would give a federal government, absolute control over your money. They could take your money, and you wouldn’t even know it was gone.”
Thank you. Very interesting.
I can see the Central Bank Digital Currency (CBDC's) he mentioned in the video being part of the Fed's effort to monitor all spending. When the current FedNow program for banks expands to individuals, I'd expect Social Security checks to be deposited into and account at the Fed, forcing the use of the CBDC's. To get to the point of total monitoring, they will have to sell the idea of replacing of cash.
https://www.federalreserve.gov/paymentsystems/fednow_faq.htm
Here:
Best if viewed on an iPad or Computer. Phones are too small.
https://oversight.house.gov/the-bidens-influence-peddling-timeline/
Joe's checks are there in the timeliness. Go look.
Got his name on the checks! Go look
It takes a lot of time to follow the timeline. It's like a detective novel, but quite interesting.
The jist of it is that there was no work performed for the millions of dollars the family took in for favors. That's the problem, in that they were bribes from foreign countries for favors. The money was laundered from China, Russia, Kazakhstan, Romania, Ukraine and other countries. The money was paid and transferred through a complex web of shell companies (LLC's), which were setup for the family. After going through the shell companies, the money ends up in Joe's and 9 of Joe's family members accounts. All this, with evidence which can be seen in the timeline.
These were the recipients:
Joe Biden’s son, Hunter Biden
Joe Biden’s brother, James Biden
Joe Biden’s brother’s wife, Sara Biden
Hunter Biden’s girlfriend or Beau Biden’s widow, Hallie
Hunter Biden’s ex-wife, Kathleen Buhle
Hunter Biden’s current wife, Melissa Cohen
Three children of the president’s son and the president’s brother
After defying a subpoena to testify, he was not charged for that crime, but was given a 2nd chance and will testify late February. Joe Biden's brother, who has been heavily involved for years will also be testifying soon.
https://oversight.house.gov/the-bidens-influence-peddling-timeline/
U.S Congressional Record:
(moderator: do not delete again, people want to know what's really going on)
https://oversight.house.gov/the-bidens-influence-peddling-timeline/
note: on this document, when you get to the bottom, hit "Load More" a couple times to see all. Also, this timeline gets updated as more info continues to accumulate.